Citigroup Issues Buy Rating for Cytokinetics Amid High Upside

Investors interested in Cytokinetics should note Citigroup’s new Buy recommendation. The report highlights a significant potential upside of nearly 97%, along with a dramatic projected revenue increase for the company.

Date: 08-02-2025

AI Rating: 7

Cytokinetics Overview

According to the report, Citigroup has initiated coverage of Cytokinetics with a Buy recommendation on February 7, 2025. This designation typically aims to attract investor interest and can positively impact stock prices.

**Price Forecast**

As of January 29, 2025, the average projected price target for Cytokinetics is $84.12 per share. This target suggests a dramatic potential increase of 96.73% from the current closing price of $42.76. Such a high upside can entice more investors, potentially driving the stock price higher as market participants respond to this bullish outlook.

**Revenue Increase**

The report also mentions projected annual revenue for Cytokinetics at $354MM, with a staggering increase rate of 10,895.34%. This indicates a strong growth potential, which is a crucial factor for investors assessing the company’s future performance.

**Earnings Per Share (EPS)**

Another critical point mentioned in the report is the projected non-GAAP EPS of -3.99. While EPS represents projected losses, it is essential for investors to consider this in relation to the high upside forecast. Companies in their growth phase often have negative EPS as they invest heavily, so this number alone should not deter interest.

**Institutional Sentiment**

The report notes that there are 792 funds reporting positions in Cytokinetics, a decrease of 2.34% from the previous quarter, which suggests some caution among institutional investors. However, the average portfolio weight dedicated to Cytokinetics has increased by 14.39%. Moreover, total shares owned by institutions saw a rise of 6.46% to 158,769K shares, indicating some confidence in the stock despite a minor drop in the number of funds holding the stock.

**Conclusion**

The combination of a strong price target upside, significant projected revenue growth, and the interest from institutional investors could result in a positive response from the stock market. However, investors should also monitor the negative EPS projection, as it reflects ongoing losses. Overall, the bullish sentiment from Citigroup can be a significant factor in driving stock prices for Cytokinetics upwards.

Stocks: CYTK